Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Youichi Makari
Observed names:
Y Makari,
Y. Makari,
Youichi MAKARI
Institutions:
Sakai City Medical Center,
Kindai University Nara Hospital
Observed institutions:
Sakai City Medical Center,
Kawanishi City Hospital,
Kindai University Nara Hospital,
The University of Osaka
OpenAlex ID:
A5089280013
The activation of Akt during preoperative chemotherapy for esophageal cancer correlates with poor prognosis
2008
·
Akiko Yoshioka
, Hiroshi Miyata
, et al.
·
Oncology Reports
·
56
PDF
Comparison of S-1–cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials
2020
·
Hisato Kawakami
, Kazumasa Fujitani
, et al.
·
International Journal of Clinical Oncology
·
6
Randomized phase II study to compare docetaxel plus S-1 with cisplatin plus S-1 in advanced gastric cancer without measurable lesions (HERBIS-3).
2018
·
Jin Matsuyama
, Yukinori Kurokawa
, et al.
·
Journal of Clinical Oncology
·
2
A case of von recklinghausen's disease associated with cancer of the ascending colon.
2001
·
Keiji UCHIDE
, Masaki KASHIWAZAKI
, et al.
·
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
·
2
PDF
[Improvement of Pain Control after Dealing with Chemical Coping-A Case of Local Recurrence of Rectal Cancer].
2018
·
Hidemi Nishi
, Yoichi Ohtake
, et al.
·
PubMed
·
1
2280 Comparison of 5-year postoperative effects after Billroth I and Roux-en-Y reconstruction following distal gastrectomy for gastric cancer: Results from a multi-institutional RCT
2015
·
Y. Kimura
, S. Takiguchi
, et al.
·
European Journal of Cancer
·
1
Comparing five-weekly S-1 plus cisplatin with tri-weekly capecitabine plus cisplatin in patients with HER2-negative recurrent gastric cancer after S-1 adjuvant therapy or chemotherapy naïve advanced gastric cancer: A pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.
2020
·
Jin Matsuyama
, Hisato Kawakami
, et al.
·
Journal of Clinical Oncology
Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC): OGSG 1105 HERBIS-4A trial.
2018
·
Atsushi Takeno
, Youichi Makari
, et al.
·
Journal of Clinical Oncology
[A case of hepatic metastasis of gastric cancer responding to TS-1, administered for two consecutive weeks and one week rest].
2001
·
S Doi
, T Yanagisawa
, et al.
·
PubMed
Development of a Gastrojejunocolic Fistula after Gastrectomy for Duodenal Ulcer Perforation.
1999
·
Keiji Uchide
, Masaki Kashiwazaki
, et al.
·
日本消化器外科学会雑誌
PDF
Show more works
View as search
Works count:
10
Citation count:
68
H-index:
2
I10-index:
1
Year
Topic
Type
